Phase 4 Hypertension Trial, Recruiting NCT06093932 Sponsor: Xiyuan Hospital of China Academy of Chinese Medical Sciences Condition: Hypertension
Back to Hypertension

Phase 4 Hypertension Trial, Recruiting

NCT06093932
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged between 35 and 65 years old, of any gender
  • People diagnosed with mild (Grade 1) high blood pressure
  • People who are either not currently taking any blood pressure medication, or who have been taking it inconsistently in the past
  • People who are willing to sign a consent form agreeing to take part

Who may not be able to join:

  • People with significant liver or kidney problems, including certain abnormal blood test results related to liver or kidney function
  • People with digestive or stomach conditions that could affect how the body absorbs medication
  • People who have a known allergy to the medication being used in this trial
  • Women who are pregnant or breastfeeding, and men who are planning to father a child within the next six months
  • People who have other serious major illnesses or any form of cancer
  • People who have high cholesterol or high blood fats, whether or not they are taking medication for it
  • People with certain heart or blood vessel changes, such as an enlarged heart muscle, reduced blood flow in the legs, or thickening or build-up of fatty deposits in the artery walls (confirm with trial site for exact measurements)
  • People who have complications related to high blood pressure, including stroke-related conditions, other heart conditions, kidney disease, peripheral artery disease, eye damage from high blood pressure, or diabetes
  • People with other serious health conditions that the trial team considers unsuitable for participation (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 12 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Hao Xu, Prof., Xiyuan Hospital of China Academy of Chinese Medical Sciences

Phone: 010-62835342

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Registry
ClinicalTrials.gov
Start date
7 April 2024
Est. completion
1 December 2024

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Change from Baseline in the Mean 24h Systolic Blood Pressure at 4,12 weeks

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov